Full details can be found in the publication: Link Professor David Harrison, NuCana’s Head of Translational Medicine, stated: “We previously presented data on NUC-3373’s ability to elicit the release ...

NuCana (NCNA) announced that initial data from the ongoing Phase 1b/2 modular study investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors ...

European equities traded in the US as American depositary receipts were tracking sharply lower late Tuesday morning, declining 1.71% to 1,313.74 on the S&P Europe Select ADR Index. From continental ...

New research on a chemical substance from caterpillar fungus, known for its potential as a cancer treatment.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.